Capgemini – Health Revolution, 2024

Capgemini's Health Revolution, 2024 report presents the latest assessment of connected health maturity and adoption in the biotechnology, pharmaceutical (biopharma), and MedTech industries. The report shows that a large majority of life sciences organizations have connected health products on the market or in development, with an expected 22% contribution to total revenue by 2028. In the biopharma industry, there has been a significant increase in connected health offerings, with a focus on preventive care, as well as emerging areas like mental health and diabetes. MedTech companies have successfully commercialized connected health products, but there is room for improvement in digital and collaborative capabilities. Mobile apps and AI technologies are widely deployed in the industry, aiming to enhance patient support and personalized care. The report highlights challenges in strategy, governance, funding, and talent that hinder successful connected health portfolio development, and proposes seven practical recommendations for industry stakeholders to drive positive outcomes.